{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-001763","form_type":"8-K","ticker":"LIXT","cik":"0001335105","company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.379630+00:00","generated_at":"2026-05-24T01:35:59.054761+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Lixte launches pre-clinical study of LB-100 to target pre-cancerous cells with NKI","bullets":["New pre-clinical study tests if initiated cells with mutant RAS oncogene can be eliminated by LB-100.","Collaboration with Netherlands Cancer Institute; led by Dr. René Bernards, NKI senior scientist and LIXTE board member.","Study in animal models expands on LIXTE’s ongoing clinical trials for ovarian and colorectal cancers.","LB-100 has shown patient tolerance with little toxicity in Phase 1 clinical trials."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-001763","json":"https://secwatch.observer/filing/0001641172-25-001763.json","markdown":"https://secwatch.observer/filing/0001641172-25-001763.md","text":"https://secwatch.observer/filing/0001641172-25-001763.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1335105/000164117225001763/0001641172-25-001763-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1335105/000164117225001763/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T01:35:59.054761+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}